Taysha Gene Therapies announced a public offering of 32.5 million common shares at $6.00 each and pre-funded warrants for 833,333 shares at nearly $6.00 each, aiming to raise about $200 million before expenses. The offering includes a 30-day option for underwriters to buy an additional 5 million shares. Proceeds will support Taysha's development of gene therapies for severe CNS diseases, including Rett syndrome. The offering is expected to close around June 26, 2026, with major banks managing the deal.
Mesoblast Limited has drawn $50 million from a new five-year loan facility provided by a shareholder, replacing higher-cost short-term debt. This move strengthens Mesoblast's balance sheet by lowering interest costs and removing short-term obligation...
HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 mont...
Western Union and Intermex announced that regulatory approvals for Western Union's acquisition of Intermex have been received from 51 U.S. states and international jurisdictions, with only one U.S. state, New York, pending approval. Both companies ar...
Modern Therapy Group has introduced a virtual intensive outpatient program (IOP) designed for adults dealing with depression, anxiety, trauma, and other mental health issues. This program offers structured, clinician-led treatment five days a week vi...
Bitcoin is showing signs of potential volatility with growing concerns about maintaining the $60,000 level. Deposits of Bitcoin into exchanges have surged to multi-month highs, a pattern historically linked to price declines below key psychological l...
